CSPC Pharmaceutical Group (HK:1093) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials for its new long-acting semaglutide injection, SYH9017. This innovative product aims to improve patient adherence by extending dosing to once a month for weight management in overweight or obese adults. The approval marks a significant step for CSPC’s development of long-acting GLP-1 receptor agonists, with potential additional benefits for type 2 diabetes and cardiovascular risk reduction.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
